The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Outcomes in patients with first-relapsed childhood ALL in Japan: Results from the JPLSG-ALL-R08 study
|
The JPLSG-ALL-R08 study was a two-part, prospective multicenter study of first-relapsed patients with childhood ALL.1 The ALL-R08-I part (UMIN000002026; n = 82) was a prospective observational study assessing outcomes of first-relapsed patients with childhood ALL in Japan. The second part, ALL-R08-II (UMIN000002025; n = 77), was a phase II trial assessing the efficacy and safety of ALL-REZ BFM-type treatment in patients with intermediate-risk first-relapsed ALL. Patients in ALL-R08-II with an unsatisfactory MRD response post-induction received allo-HSCT. Patients were risk-stratified according to the BFM-S risk stratification. Results from this study were published in Pediatric Blood & Cancer by Yamanaka et al.1 |
| Key learnings |
|
In the ALL-R08-I cohort, among patients classified as S1 (standard-risk group), S2 (intermediate-risk group), S3 and S4 (high-risk groups), and post-HSCT, the 3-year probability of EFS was 83%, 37%, 28%, 14%, and 0%, respectively, and the 3-year probability of OS was 100%, 73%, 53%, 27%, and 0%, respectively. |
|
In the ALL-R08-II cohort, the 3-year EFS and OS rates were 65% and 83%, respectively. The 3-year EFS rates were 70% vs 68% (p = 0.591) and 3-year OS rates were 93% vs 87% (p = 0.731) in MRD-negative (<10−3) and MRD-positive patients (≥10−3), respectively. These findings suggest that selecting patients for allo-HSCT based on post-induction MRD response can improve outcomes. |
|
This study confirms the efficacy of ALL-REZ BFM-type treatment in pediatric patients with relapsed ALL in Japan and reinforces the utility of MRD assessment in guiding treatment decisions. The results of the ALL-R08 study can serve as a historical control for future trials of novel agents for pediatric patients with relapsed ALL in Japan. |
Abbreviations: ALL, acute lymphoblastic leukemia; ALL-REZ BFM, Acute Lymphoblastic Leukemia Relapse Study of Berlin–Frankfurt–Münster; allo-HSCT, allogeneic hematopoietic stem cell transplantation; EFS, event-free survival; JPLSG, Japanese Pediatric Leukemia/Lymphoma Study Group; MRD, measurable residual disease; OS, overall survival.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
On average, how many patients with T-cell acute lymphoblastic leukemia do you see in a year?
